C4 Therapeutics, Inc. (CCCC)

Over the past six months, C4 Therapeutics' stock price decreased by 35.96%, closing at $1.71 on February 5, 2026. The company's market capitalization as of February 4, 2026, was $183.17 million, reflecting a decrease of 2.59% over the past 30 days and 1.05% over the last 12 months. Insider selling occurred, including a sale by Leonard Reyno on January 17, 2026. C4 Therapeutics outlined strategic milestones to advance Cemsidomide and its discovery strategy on January 14, 2026. The company announced an inducement grant on January 26, 2026. Analysts gave C4 Therapeutics a consensus rating of "Moderate Buy" as of February 1, 2026, but a price target was decreased by 13.75% to $10.05 on February 4, 2026. C4 Therapeutics participated in the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 4, 2026. C4 Therapeutics reported a revenue decline of 26.90% in the quarter ending September 30, 2025.

As a clinical-stage biopharmaceutical company, C4 Therapeutics, Inc. is primarily focused on the discovery and development of novel therapeutic candidates rather than the commercial sale of established products. Therefore, traditional "demand seasonality" for its products and services, in the sense of fluctuating consumer purchasing patterns, is not directly applicable. The company's revenue is often derived from collaborations and milestone payments rather than direct product sales.

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing targeted protein degraders for diseases, especially in oncology and immuno-oncology. They utilize their proprietary CiD and Degronimid platforms to eliminate disease-causing proteins by leveraging the body's natural protein disposal system. Their pipeline includes Cemsidomide, in Phase 1/2 trials for multiple myeloma and lymphomas; CFT1946, in Phase 1/2 trials for melanoma, colorectal cancer, and other solid malignancies; and CFT8919, an EGFR degrader for non-small cell lung cancer.

C4 Therapeutics, Inc. is headquartered in Watertown, Massachusetts, United States. The company operates research laboratories within the United States and engages in collaborations with academic institutions and contract research organizations globally.

C4 Therapeutics has maintained a "Moderate Buy" consensus rating from analysts, with an average rating score of 2.50. MarketBeat evaluated C4 Therapeutics as scoring higher than 54% of companies and ranking 508th out of 872 stocks in the medical sector. While no specific events explicitly detailing a negative impact on "brand reputation" were found, the decrease in stock price over the past year and recent insider selling could be perceived negatively by investors. Conversely, outlining strategic milestones and participation in industry summits could contribute positively to its reputation within the scientific and investment communities.

C4 Therapeutics, Inc. has a diverse ownership structure, including institutional investors, insiders, and public/individual investors. Approximately 12.37% of the company's stock is owned by Institutional Investors, 1.65% by Insiders, and 85.98% by Public Companies and Individual Investors. Major institutional owners and shareholders include Lynx1 Capital Management LP, Soleus Capital Management, L.P., Orbimed Advisors Llc, WAMCX - Wasatch Ultra Growth Fund Investor Class shares, Morgan Stanley, Wasatch Advisors Inc (also listed as Wasatch Advisors LP), Vanguard Group Inc, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Bank Of America Corp /de/, Millennium Management Llc, Point72 Associates, LLC and Point72 Asset Management, L.P., RA Capital Management, L.P. and RA Capital Healthcare Fund, L.P., Betta Pharmaceuticals Co., Ltd., and Blackrock, Inc.